Longeveron (LGVN) vs Skye Bioscience (SKYE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Longeveron is the larger company by market cap ($7.9 million vs $7.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | LGVN | SKYE |
|---|---|---|
| Share price | $2.48 | $1.69 |
| Market cap | $7.91M | $7.48M |
| 1-day change | +4.64% | +0.60% |
| EPS (TTM) | $-9.90 | $-10.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.30 | $14.08 |
| 52-week low | $2.30 | $1.50 |
| Distance from 52-week high | -79.84% | -88.00% |
| Analyst consensus | none | none |
| Avg. price target upside | +2369.76% | +3923.67% |
| Average volume | 92.38K | 89.28K |
| Shares outstanding | 3.04M | 4.43M |
| Employees | 38 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Longeveron
LGVN stock →Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States. Its lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors which is in phase 3 clinical trial to treat hypoplastic left heart syndrome; completed phase 2a clinical trial to treat Alzheimer's disease, as well as in phase 2b clinical trial to treat aging frailty.
Health Care · Biotechnology: Pharmaceutical Preparations · 38 employees
About Skye Bioscience
SKYE stock →Skye Bioscience, Inc., a clinical-stage biotechnology company, develops molecules that modulate G-protein-coupled receptors to treat obesity, overweight, and related metabolic diseases. The company's lead clinical asset is nimacimab, a peripherally-restricted negative allosteric modulating antibody targeting cannabinoid receptor 1 (CB1) administered as a subcutaneous injectable, which targets CB1 receptors in peripheral tissues including adipose, liver, and muscle tissues with limited central nervous system accumulation.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
LGVN vs SKYE FAQ
Which is bigger, Longeveron or Skye Bioscience?
Longeveron (LGVN) is larger, with a market capitalization of $7.91M compared with $7.48M for Skye Bioscience (SKYE).
Are Longeveron and Skye Bioscience in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.